Longboard Pharmaceuticals — Biomedical Watch V2

Traitements4programmes

Essais3liés

Publications3liées

SourceDBlocale

Traitements

4

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
LP352This (DEEp OLE Study) is a multicentre, open-label study to investigate the long-term safety, efficacy, tolerability, and pharmacokinetics (PK) of LP352 in the treatment of seizures in children and adults with DEE who completed Study LP352-301 or LP352-302. The study consists of 3 main phases: Screening, Titration period and Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 14 months.	Épilepsie	Phase 3	À vérifier	United States, Australia, Belgium, Brazil, Canada, China, Denmark, Finland, …	À vérifier
LP352This (DEEp OLE Study) is a multicentre, open-label study to investigate the long-term safety, efficacy, tolerability, and pharmacokinetics (PK) of LP352 in the treatment of seizures in children and adults with DEE who completed Study LP352-301 or LP352-302. The study consists of 3 main phases: Screening, Titration period and Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 14 months.	Épilepsie	Phase 3	À vérifier	United States, Australia, Belgium, Brazil, China, France, Germany, Italy, Japan, Latvia, Portugal, Serbia, Spain, United Kingdom	À vérifier
LP352This (DEEp OLE Study) is a multicentre, open-label study to investigate the long-term safety, efficacy, tolerability, and pharmacokinetics (PK) of LP352 in the treatment of seizures in children and adults with DEE who completed Study LP352-301 or LP352-302. The study consists of 3 main phases: Screening, Titration period and Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 14 months.	Épilepsie	Phase 3	À vérifier	United States, Australia, Belgium, Brazil, Canada, China, France, Germany, Italy, Japan, Latvia, Mexico, Netherlands, Portugal, Serbia, Spain, United Kingdom	À vérifier
LP352This (DEEp OLE Study) is a multicentre, open-label study to investigate the long-term safety, efficacy, tolerability, and pharmacokinetics (PK) of LP352 in the treatment of seizures in children and adults with DEE who completed Study LP352-301 or LP352-302. The study consists of 3 main phases: Screening, Titration period and Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 14 months.	Épilepsie	Phase 3	À vérifier	United States, Australia, Belgium, Brazil, Canada, China, Denmark, Finland, France, Germany, Italy, Japan, Latvia, Mexico, Portugal, Serbia, Spain, United Kingdom	À vérifier

Essais cliniques

3

Molécule	Indication / population	Phase	NCT	Titre	Statut
LP352	Épilepsie	Phase 3	NCT06660394	A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)	RECRUITING
LP352	Épilepsie	Phase 3	NCT06719141	A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)	ACTIVE_NOT_RECRUITING
LP352	Épilepsie	Phase 3	NCT06908226	A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)	ENROLLING_BY_INVITATION

Publications

3

Molécule	Indication / population	Titre	Journal	Date
LP352		Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Bexicaserin in Healthy Participants: A First-in-Human Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Escalation Phase 1 Study.	Clinical pharmacology in drug development
LP352		Bexicaserin for the treatment of seizures in developmental and epileptic encephalopathies: A phase 1b/2a trial (PACIFIC).	Epilepsia
LP352		Development and Validation of an LC-MS/MS Method for the Quantitative Estimation of Bexicaserin in Human Cerebrospinal Fluid.	Biomedical chromatography : BMC